On July 21, DotBio-B declined 5.15% in regular trading, trading at 230.2 HKD/share, with turnover of approximately HKD 54.22 million. The broader biotechnology sector showed widespread weakness, with BEIGENE down 1.78%, AKESO down 2.52%, INNOVENT BIO down 2.11%, SKB BIO down 0.79%, and 3SBIO down 2.07%.

The pullback follows the stock's strong rally in the prior session, during which shares surged as much as 15% after the company's B7-H3 ADC DB-1311/BNT324 was proposed for breakthrough therapy designation by CDE for the treatment of metastatic castration-resistant prostate cancer, and initial Phase I/IIa clinical data for DB-1310 in advanced solid tumors was disclosed at ASCO. Sector-wide selling pressure amid a generally weaker biotech tape appears to have triggered profit-taking following the previous day's significant gains.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)